Bionano Genomics, Inc. Operating Income Loss

• Bionano Genomics, Inc. showed an increase of +67.9% in Operating Income Loss from 2024 to 2025.
• This data is from Bionano Genomics, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
• XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 9 years of available data (2017 to 2025), Bionano Genomics, Inc.'s Operating Income Loss has declined by 43.6%.
• Historical annual values: Fiscal year 2025: -$33.34 million | Fiscal year 2024: -$103.98 million | Fiscal year 2023: -$215.25 million | Fiscal year 2022: -$131.70 million | Fiscal year 2021: -$77.10 million | Fiscal year 2020: -$38.55 million | Fiscal year 2019: -$25.87 million | Fiscal year 2018: -$20.42 million | Fiscal year 2017: -$23.22 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026